Realm Thera. Share Discussion Threads

[enewman36] 18/2/2019 10:52

Well not much excitement it must be said given the news which is disappointing, plus you can buy below the mid indicating a large sell order on the books.

[the stinger] 17/2/2019 21:06

This is so far off the radar for most people...hence MM's can try shake out..not many PI holders...

[the stinger] 17/2/2019 15:10

The can make what they wish of it Arthur.... i hope the share price stays around the same tomorrow... absolute steal....buy and transfer to nasdaq...easy 100% min!!.

[arthur_lame_stocks] 17/2/2019 13:19

These are obviously value, I guess it just depends what the market makes of the delisting.

[the stinger] 15/2/2019 22:25

Cash takeover is around £22m ,, 17p a share?... now priced at 7p?....

[boystown] 15/2/2019 18:46

So $28.4m / £22m in cash, de-listing from AIM, NASDAQ listing and mkt cap of £8m?

Proposed disposal of hypochlorous acid (HOCl) Assets leaves what in other assets?

[the stinger] 14/2/2019 14:26

SP tells you different.. good luck though!!

[cjohn] 14/2/2019 10:21

In the last couple of months, I've bought a few times.


Pretty good downside protection from the cash.

[arthur_lame_stocks] 23/1/2019 11:00

The last update said the next one would be Q1 2019 so plenty of time yet before that's up.

[the stinger] 22/1/2019 13:24

Where's this update Arthur?.... been some time now!!

[arthur_lame_stocks] 21/1/2019 16:27

I bought a few more. I'm hoping that even if they can't sell the business and IP there will be enough cash left for me to get my money back.

[arthur_lame_stocks] 26/12/2018 23:56

I bought some more of these at 6p just before Christmas. At that price the discount to cash is significant with the chance of value realisation in the short term.

It seems like a really attractive risk reward situation to me.

[colin12345678] 29/11/2018 08:07

A bidding war gives a company in this positions options and the upper hand in negogiations. No wonder 81% of the stock with significant holders were happy to hold in UK & no wonder 1.3m of just 4.6m shares in issue have recently been taken up by II's on Nasdaq

[colin12345678] 29/11/2018 08:07

multiple offers and still sub cash.

[colin12345678] 29/11/2018 08:03

As part of the strategic review, Realm received multiple indications of interest which include a potential sale of the Company, contemplated as a reverse merger

[the stinger] 28/11/2018 11:37

Probs 18-20p offer

[arthur_lame_stocks] 28/11/2018 11:17

I wonder if we'll get an announcement at the end of the week. That's when the time is up for indicative offers.

[cerrito] 01/10/2018 20:12

A_L_S
I can well understand why you did what you did given that as per my calculations Marcap is approx £10.5m and June cash minus current liabilities is a bit over £15m.
I sold out August 14/15.
I do not see their IP being worth much and have no feel for how much their tax losses are worth.
I doubt if you will loose money especially as the big shareholders will want a speedy resolution but do not see myself joining you.

[arthur_lame_stocks] 26/9/2018 16:41

Well I had a small punt on these today based on the cash burn dropping dramatically so that the discount to cash is not quickly eaten up and there being some further value in the IP and accumulated losses (which are very large).

Not a big punt, just some fun money as it could all go wrong.

[edmonda] 15/8/2018 08:32

AIM:RLM - "Review underway after Atopic Dermatitis miss"

RLM’s randomised, double-blind, placebo controlled, Phase II clinical trial, PR022 showed no difference from vehicle in the primary endpoint of percentage change in Eczema Area Severity Index (EASI) versus baseline. The Company is now analysing the data to interpret the top-line result, as well as the other data collected in the study.
The conclusions of this review will be used to inform decision-making going forward, and this includes evaluating the implications of these data for RLM’s preclinical HOCl dermatology pipeline in Acne and Psoriasis – both of which had been making good progress. RLM indicates that it will also review the possibility of acquiring one or more new assets, although no specific detail is available. They expect to disclose the outcome of the review in September.
Pending the outcome of the review, we are suspending our forecasts and valuation that we can update when the Group’s strategic direction becomes clearer in September. In the meantime, RLM has the benefit of significant cash on the balance sheet, an experienced Executive team, and substantial IP filed.
Read the full note here ...

[cerrito] 14/8/2018 22:32

Looking at what support their cash pile can give the share price
They have 116 m shares and at the end of June US23m. Cash burn in H1 was US10m, including the NASDAQ listing costs.
I am assuming they have reduced R&D on acne/ psioriasis to the minimum until next month when they make their review. At the end of Sept cash/ cash equivalents I estimate will be Us20m approx or approx 13.5p per share.
Of course in the extremely unlikely event that they were to liquidate the company this cash balance would go down to say 11p a share after the costs of liquidation offset by the sale of their IP.
PS
Went on to the Nasdaq webpage to see what RLM did there but said price unchanged at $0 and no trades so perhaps RLM not live on NASDAQ yet.

[cerrito] 14/8/2018 13:36

Nothing new in the conference call. Just said what they said in the RNS that the information given was hot off the press and that need to digest it and in September there will be an update with how they will proceed with PRO22/AD as well as the acne and psioriasis programme or indeed buying some of the other assets they are looking at.

They do have US23m in cash/equivalents and will not have the repeat of the US 1.5 m spent on the NASDAQ listing which will be enough to take the acne and psioriasis programme a good way forward.
Rather kicking myself for not asking him how the scientists say this AD result affects their view of how the acne and/or psioriasis results will work out.
I need to decide what to do with the fat end that I have
PS
Not speaking at the conference this afternoon

[danieldanj] 14/8/2018 12:37

Realm Therapeutics (RLM) News Out Just Now